Datopotamab Deruxtecan in Advanced or Metastatic …
WEBApr 23, 2024 · Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker.
Datopotamab deruxtecan showed median overall survival of 14.6 …
WEBSep 9, 2024 · Presidential Symposium for NeoCOAST-2 demonstrates potential for datopotamab deruxtecan plus Imfinzi and chemotherapy in neoadjuvant early-stage non-small cell lung cancer. Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd ...
Datopotamab deruxtecan met dual primary endpoint of …
WEBJul 3, 2023 · Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody …
WEBAug 21, 2021 · Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and eva ….
Datopotamab deruxtecan showed clinically meaningful overall …
WEBMay 27, 2024 · Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo.
Datopotamab Deruxtecan, a Novel TROP2-directed …
WEBDec 12, 2021 · We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and evaluated its antitumor activity and safety profiles in preclinical models.
Datopotamab deruxtecan improved progression-free survival vs ...
WEBOct 23, 2023 · Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of six ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform.
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab …
WEBDec 18, 2023 · TROPION-Breast03 is evaluating datopotamab deruxtecan with and without durvalumab versus investigator’s choice of therapy in patients with stage I to III TNBC with residual disease after neoadjuvant therapy.
Datopotamab deruxtecan showed clinically meaningful overall …
WEBMay 27, 2024 · Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.
Datopotamab–deruxtecan in early-stage breast cancer: the
WEBSep 14, 2024 · Okajima, D. et al. Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol ...
Skip to content